Key Takeaways
- ZIVO Bioscience completed a second collaborative study with the University of Delaware to assess its proprietary algal-derived formulations in mitigating Low Pathogenicity Avian Influenza (LPAI) spread.
- The study identified a lead formulation showing slower virus transmission and possible protective effects in poultry.
- Modest trends in reduced viral shedding were noted among directly challenged birds.
- The company submitted a $5.5 million funding request to Michigan and is applying for USDA’s $100 million Avian Influenza Poultry Innovation Grand Challenge.
- Further large-scale research is planned to validate these initial observations.
ZIVO Bioscience expands research with promising LPAI mitigation results
ZIVO Bioscience, Inc. (OTCQB: ZIVO) announced positive results from its second collaborative study with the University of Delaware, further evaluating the efficacy of its proprietary algal-derived active ingredients in controlling Low Pathogenicity Avian Influenza (LPAI) transmission among poultry.
Building on earlier research, this study compared three different formulations of ZIVO’s compounds across two scenarios: directly challenged birds and contact-exposed birds. The outcomes suggested potential benefits in reducing virus transmission dynamics and identified the most promising formulation for further development.
“These findings reinforce our commitment to non-antibiotic solutions for the poultry industry,” said John Payne, Chairman and CEO of ZIVO Bioscience. “Identifying a superior formulation will be key as we progress into larger trials.”
Lead formulation shows slower virus transmission
The most notable findings came from the transmission-focused arm of the study. Birds treated with a blend of four distinct algal-derived ingredients exhibited slower and less efficient virus spread. One treated bird did not show signs of infection after exposure, highlighting the formulation’s potential protective capabilities.
In the group of birds directly challenged with LPAI, modest trends in reduced viral shedding were observed among ZIVO-treated subjects compared to untreated controls. While these results did not reach statistical significance, they provide encouraging early signals.
“Any positive trend observed in these early-stage studies is very encouraging,” said Brian Ladman, PhD, Principal Investigator at the University of Delaware. “Delaying transmission can provide important advantages for poultry producers managing at-risk flocks.”
Funding requests submitted to advance research
Following these promising results, ZIVO Bioscience has submitted a $5.5 million funding request to the State of Michigan to support continued research. The company is also pursuing funding through the USDA’s $100 million Avian Influenza Poultry Innovation Grand Challenge.
“Given the widespread impact of avian influenza on U.S. poultry, our solution offers significant potential benefits,” Payne added. “Additional funding would accelerate our efforts to bring this technology to market.”
Next steps include larger-scale validation for ZIVO Bioscience
ZIVO Bioscience intends to continue working with the University of Delaware on a larger-scale project that will focus on the lead formulation identified in this study. The objective will be to validate the reproducibility of the findings and further explore the product’s application in commercial poultry environments.
The company remains dedicated to advancing its algal-derived product pipeline aimed at supporting poultry health, productivity, and sustainable disease management.
1 Comment